Replies to post #153276 on Biotech Values

[poorgradstudent]

lol, so, i guess you don't have much respect for ARRY.

I think respect is the wrong word. I will say that I've just not been compelled to own it; note that this could be out of ignorance just as easily as it could be an informed choice.

But there are two points that do not draw me to ARRY:

1) Out of coincidence, I've been invested in 3 companies now that have had drug approvals in myeloma. All three received approval as a single agent. To me this says that monotherapy is the easiest way onto the market for this cancer provided the drug has sufficient activity. That ARRY is looking at a combination trial suggests to me that their drug's activity is not as compelling in this indication.

2) I've made better money from companies that had sole ownership of their lead drug at the time that I invested. I'm too late here as selumetinib is already in someone else's hands.